Launch drift is the gap that emerges between an organization's original go-to-market strategy and how that strategy is executed in the field. Over decades, pharmaceutical manufacturers spend billions in product development and launch preparation only to face actual execution falling short of expectations, or in some cases, failing altogether.

Indeed, McKinsey research reports that roughly two-thirds of pharmaceutical product launches fail to meet their first-year commercial expectations, with a meaningful share never recovering momentum in subsequent years.[1]

Identifying launch drift, understanding the root cause of the drift, and how to regain momentum is critical to avoid these costly setbacks. Yet, organizations often struggle to determine whether disappointing performance stems from a flawed strategy or poor execution. In reality, the answer is rarely one or the other.

Most launch drift results from a combination of strategic and executional factors that compound over time in ways that aren't always immediately visible. Recognizing these factors early, and responding effectively, will make the difference between meeting launch expectations and falling short.

The search for clarity on launch drift causation

Rapidly diagnosing the root causes of launch drift is essential to maintaining commercial momentum. Whether the issue lies in field messaging, HCP perceptions of product differentiation, or evolving prescribing patterns, identifying the underlying issues early can help prevent the gap between launch intent and market reality from widening.

Launch drift can start as early as day one. Organizations should immediately implement launch performance monitoring, but must balance speed to react with overreaction to provide enough time for meaningful market signals to emerge. After four to six weeks, early trends should begin to take shape, providing an opportunity to identify potential issues. By approximately three months, organizations typically have sufficient data to determine whether true launch drift is occurring.

Launch drift is typically recognized through the underperformance in prescription volume or market penetration, or the lack of change in physician behavior. This may include HCP reluctance to prescribe the product for appropriate patients, recommend it to colleagues, or refer patients to appropriate specialists.

There are many factors which can contribute to this performance gap, and it is crucial to identify them in order to course correct. Some of the basic questions to address in understanding causation might include:

• How well does the market understand your product?
• Who will write the product at launch?Are the HCP targets identified through pre-launch target activities accessible, and the actual writers of the product? Are the reps following the target list?
• How well do the targeted HCPs understand the disease state, MOA, and clinical benefits of the product? Does the messaging help HCPs overcome widely held beliefs?
• How aligned are the field teams to launch strategy? Do they believe in the brand story, messaging, and their ability to win against competition?
• What actually happens when field teams are in front of customers executing the launch strategy? If a customer questions when to use a new therapy (or new class of therapy), do reps hold firm in their messaging or divert to what’s safe when a customer pushes back?

While evaluating these factors, organizations must also account for payer dynamics. Prior authorization requirements, step therapy, and reimbursement barriers can suppress new and total prescription volumes, masking otherwise positive HCP perceptions and engagement.

Applying diagnostic intelligence to drive targeted action

Answering these questions provides the diagnostic intelligence needed to understand what is happening in the field and make timely, targeted adjustments that realign execution with strategic intent.

To gather this intelligence, stakeholder interviews with experts in each discipline and in-field observations should be conducted. These will result in a robust dataset of real-world evidence from which hypotheses on drift causation can be built. From here, it is imperative to rapidly test these hypotheses through structured prototypes or pilots using an intelligent, data-driven design approach to enable clear decision making from the pilot results

A case in point, involved a global pharmaceutical company in a highly competitive specialty market. Leadership sought to understand why their launch performance was falling short despite significant investment and preparation.

By combining observations of field teams’ execution; and HCPs recall, perceptions about the brand vs. competitors, and prescription behavior into one connected commercialization diagnostic, root causes of the drift were identified.

This integrated diagnosis provided leadership with a clear, and decision-ready understanding of where launch execution was drifting, why recalled messages were not translating into meaningful differentiation, and which interventions would have the greatest commercial impact.

As a result, the organization reordered its message hierarchy to prioritize the points most likely to differentiate the product in physicians’ minds. A competitor and objection-handling playbook, alongside scenario-based training to improve consistency in challenging field interactions, was also developed. These messaging adjustments were made within a few weeks, with field training following soon after.

In addition, the organization introduced case-based training designed to broaden patient identification beyond the most obvious prescribing segments, helping unlock additional market opportunity.

As a result of this quick response to launch drift, we learned anecdotally of stronger rep confidence to win against competition within approximately two months. A follow up assessment wave conducted at six months showed desired change in HCP behavior.

A second case example is that of a manufacturer launching a new medication to treat liver disease. The company’s launch strategy focused on maximizing the number of physician presentations, assuming that the product’s clinical profile would easily drive script writing. Instead, physician behavior did not change.

After diagnostic intelligence was gathered, it was determined that the manufacturer needed a message depth strategy to better educate the HCPs to change years of former prescribing behavior, rather than continue the reach strategy it was pursuing.

The evolving role of commercial intelligence

Despite the ubiquity of data, it can still be difficult to home in on the best strategic approach. Today, with more data being collected than ever before, expectations are launch teams will make effective, data-informed decisions.

However, many companies have a partial view of HCPs that can lead to error due to small sample sizes emanating from limited interactions and disintegrated data due to firewalls within the organization. Either or both create an incomplete picture of launch performance and limit timely decision-making.

Overall, when done correctly, commercial intelligence includes:

• Shared activity across teams
• Compliant integration of Medical Information interactions
• Full rep “free text” capture
• Enhanced digital data capture across messages and sentiment

When faced with launch drift, the pressure to respond quickly is significant. Advances in AI tools now makes the safe collection and analysis of data faster than ever, which can quicken the pace to strategic re-alignment. However, making sure changes are based on accurate intelligence and integrated insights is paramount.

Organizations need the ability to continuously monitor launch performance, measure progress over time, and translate field insights into strategic actions that improve execution and ultimately influence HCP behavior.

Many companies benefit from partnering with an experienced field insights organization as early as four weeks after launch to assess progress and identify emerging issues before launch drift becomes firmly established. With this complete data picture, companies can understand not only what is happening, but why it is happening to allow any needed, targeted course correction.

As commercial intelligence capabilities continue to evolve, organizations will be better positioned to enhance coordination and evolution of resource needs and deploy resources in an efficient and effective manner, further enhancing course correction efforts throughout the product life cycle.

Partnering for launch success

When launch drift occurs, many organizations benefit from an objective external perspective to identify root causes and partner to identify the best strategies on corrective actions to meet launch objectives.

Integrated commercialization partners can connect insight generation, launch planning, customer engagement, field execution, and ongoing performance assessment into a unified strategy. By combining diagnostic intelligence with the ability to rapidly deploy targeted field support when needed, these partners help organizations move quickly from identifying launch drift to restoring commercial momentum and achieving launch objectives. The more comprehensive understanding of field dynamics this partnership delivers enables timely, targeted adjustments that keep launches on track, and avoids the broad, disruptive pivots that may compromise long-term launch success.

Source

1. Drug Patent Watch: “The Definitive Pharmaceutical Drug Launch Playbook: Every Critical Mistake, Dissected,” March 22, 2026,https://www.drugpatentwatch.com/blog/mistakes-to-be-avoided-when-preparing-a-drug-launch/, accessed July 9, 2026.